HIKAL. | DISHMAN PHARMA | HIKAL./ DISHMAN PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 32.6 | 30.0 | 108.7% | View Chart |
P/BV | x | 3.5 | 3.3 | 105.5% | View Chart |
Dividend Yield | % | 0.7 | 0.7 | 112.6% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
HIKAL. Mar-21 |
DISHMAN PHARMA Mar-16 |
HIKAL./ DISHMAN PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 204 | 374 | 54.6% | |
Low | Rs | 67 | 129 | 52.1% | |
Sales per share (Unadj.) | Rs | 139.5 | 197.0 | 70.8% | |
Earnings per share (Unadj.) | Rs | 10.8 | 21.2 | 51.0% | |
Cash flow per share (Unadj.) | Rs | 17.7 | 34.7 | 51.0% | |
Dividends per share (Unadj.) | Rs | 2.00 | 2.00 | 100.0% | |
Avg Dividend yield | % | 1.5 | 0.8 | 185.4% | |
Book value per share (Unadj.) | Rs | 75.7 | 179.9 | 42.1% | |
Shares outstanding (eoy) | m | 123.30 | 80.70 | 152.8% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.0 | 1.3 | 76.2% | |
Avg P/E ratio | x | 12.6 | 11.9 | 105.9% | |
P/CF ratio (eoy) | x | 7.7 | 7.3 | 105.7% | |
Price / Book Value ratio | x | 1.8 | 1.4 | 128.2% | |
Dividend payout | % | 18.5 | 9.4 | 196.2% | |
Avg Mkt Cap | Rs m | 16,738 | 20,307 | 82.4% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 1,643 | 5,355 | 30.7% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 17,204 | 15,898 | 108.2% | |
Other income | Rs m | 50 | 265 | 18.8% | |
Total revenues | Rs m | 17,254 | 16,163 | 106.8% | |
Gross profit | Rs m | 3,229 | 4,103 | 78.7% | |
Depreciation | Rs m | 852 | 1,091 | 78.2% | |
Interest | Rs m | 362 | 944 | 38.3% | |
Profit before tax | Rs m | 2,064 | 2,334 | 88.5% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 733 | 624 | 117.5% | |
Profit after tax | Rs m | 1,331 | 1,710 | 77.9% | |
Gross profit margin | % | 18.8 | 25.8 | 72.7% | |
Effective tax rate | % | 35.5 | 26.7 | 132.9% | |
Net profit margin | % | 7.7 | 10.8 | 71.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 9,251 | 11,018 | 84.0% | |
Current liabilities | Rs m | 7,033 | 9,517 | 73.9% | |
Net working cap to sales | % | 12.9 | 9.4 | 136.6% | |
Current ratio | x | 1.3 | 1.2 | 113.6% | |
Inventory Days | Days | 26 | 57 | 46.1% | |
Debtors Days | Days | 103 | 3 | 2,945.3% | |
Net fixed assets | Rs m | 10,906 | 18,787 | 58.0% | |
Share capital | Rs m | 247 | 161 | 152.8% | |
"Free" reserves | Rs m | 9,087 | 14,354 | 63.3% | |
Net worth | Rs m | 9,334 | 14,516 | 64.3% | |
Long term debt | Rs m | 2,629 | 4,189 | 62.8% | |
Total assets | Rs m | 20,157 | 29,805 | 67.6% | |
Interest coverage | x | 6.7 | 3.5 | 193.1% | |
Debt to equity ratio | x | 0.3 | 0.3 | 97.6% | |
Sales to assets ratio | x | 0.9 | 0.5 | 160.0% | |
Return on assets | % | 8.4 | 8.9 | 94.3% | |
Return on equity | % | 14.3 | 11.8 | 121.1% | |
Return on capital | % | 20.3 | 17.5 | 115.7% | |
Exports to sales | % | 68.7 | 24.9 | 276.1% | |
Imports to sales | % | 26.9 | 3.7 | 718.8% | |
Exports (fob) | Rs m | 11,823 | 3,956 | 298.8% | |
Imports (cif) | Rs m | 4,623 | 594 | 777.9% | |
Fx inflow | Rs m | 11,823 | 4,952 | 238.8% | |
Fx outflow | Rs m | 4,623 | 697 | 663.6% | |
Net fx | Rs m | 7,200 | 4,255 | 169.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 2,290 | 2,786 | 82.2% | |
From Investments | Rs m | -1,562 | -1,529 | 102.2% | |
From Financial Activity | Rs m | -969 | -941 | 102.9% | |
Net Cashflow | Rs m | -240 | 317 | -76.0% |
Indian Promoters | % | 68.8 | 61.4 | 112.0% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 4.8 | 23.0 | 20.9% | |
FIIs | % | 3.9 | 12.0 | 32.7% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 31.2 | 38.6 | 80.9% | |
Shareholders | 79,105 | 52,291 | 151.3% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare HIKAL. With: SUN PHARMA DR. REDDYS LAB LUPIN CIPLA AUROBINDO PHARMA
Indian share markets rose today tracking the rally in US stocks after softer-than-expected US inflation data stoked speculation the Federal Reserve could pivot to a shallower pace of interest-rate hikes.